Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315375 | 1.00 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL1168135 | 1.00 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL20518531 | 1.00 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL21014430 | 0.83 | LMNA (0.50) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL29620322 | 0.83 | LMNA (0.50) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL2480041 | 0.80 | USP2 (0.39) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL26092953 | 0.80 | USP2 (0.39) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL19383666 | 0.78 | LMNA (0.36) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL6629736 | 0.77 | SLC22A6 (0.50) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL19331126 | 0.77 | SLC22A6 (0.50) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111638363-B | 3-deoxyfructose rapid quantitative fluorescence detection device and preparation method thereof | 吉林省格瑞斯特生物技术有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-111638363-A | 3-deoxyfructose rapid quantitative fluorescence detection device and preparation method thereof | 吉林省格瑞斯特生物技术有限公司 | 2020-09-08 | — | — | CN | claimed |
| CN-108902304-A | A kind of the brown fermented milk beverage and its processing method of low 3- deoxyfructose and 5 hydroxymethyl furfural content | 南开大学 | 2018-11-30 | — | — | CN | claimed |
| JP-4738554-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| CN-1919201-A | Compounds and methods for therapeutic intervention in preventing diabetic complications | FOX CHASE CANCER CT (US) | 2007-02-28 | — | — | CN | claimed |
| CN-1148185-C | Inhibitor for generation of 3-deoxyglucurone | �ձ���ҩ��ʽ���� | 2004-05-05 | — | — | CN | claimed |
| EP-1085885-B1 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CT (US) | 2003-10-01 | — | — | EP | claimed |
| EP-1021175-A4 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2002-08-28 | — | — | EP | claimed |
| JP-2001512424-A | — | — | 2001-08-21 | — | — | JP | claimed |
| EP-1021175-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-07-26 | — | — | EP | claimed |
| CN-1251521-A | Compounds and methods for therapeutic intervention in preventing diabetic complications | FOX CHASE CANCER CENTER (US) | 2000-04-26 | — | — | CN | claimed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | claimed |
| CN-1185948-A | Inhibitor for generation of 3-deoxyglucurone | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | claimed |
| EP-3778580-B1 | SYNTHESIS OF FURANS FROM SUGARS VIA KETO INTERMEDIATES | BP CORP NORTH AMERICA INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-11981888-B2 | Synthesis of furans from sugars via keto intermediates | BP CORPORATION NORTH AMERICA INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11957728-B2 | Compositions for targeting receptor for advanced glycation end-products (RAGE) in a chronic inflammatory condition | SAMI-SABINSA GROUP LIMITED (IN) | 2024-04-16 | — | — | US | disclosed |
| WO-1999064561-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | disclosed |
| CN-1185948-A | Inhibitor for generation of 3-deoxyglucurone | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981888-B2 | Synthesis of furans from sugars via keto intermediates | HPD, KHK, ALDOA | USP2 2160/4885SLCO1B1 259/4885LMNA 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.